1. Home
  2. PROK

as of 12-02-2025 3:59pm EST

$2.26
$0.00
0.00%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Chart Type:
Time Range:
Founded: 2015 Country:
United States
United States
Employees: N/A City: WINSTON-SALEM
Market Cap: 417.1M IPO Year: N/A
Target Price: $6.25 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.54 EPS Growth: N/A
52 Week Low/High: $0.46 - $7.13 Next Earning Date: 11-10-2025
Revenue: $744,000 Revenue Growth: N/A
Revenue Growth (this year): 918.66% Revenue Growth (next year): N/A

AI-Powered PROK Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 70.83%
70.83%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of ProKidney Corp. (PROK)

Sell
PROK Nov 13, 2025

Avg Cost/Share

$2.37

Shares

502,136

Total Value

$1,190,062.32

Owned After

0

Sell
PROK Nov 12, 2025

Avg Cost/Share

$2.72

Shares

255,026

Total Value

$694,515.07

Owned After

0

Share on Social Networks: